NAMS — NewAmsterdam Pharma Company N.V. stock price, charts and financials

QT13NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
21.93
+0.75+3.54%
OverviewShort InterestFilings
NAMSQT13NewAmsterdam Pharma Company N.V.·NASDAQ
21.93+3.54%
News
Up 3.5% — Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock? (Yahoo).
Medium confidence
TA
Loading chart...
Signal & projected range
Insider open-market buyHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
HRMY+1.26%$42.74MLYS+1.60%$27.98VRDN-2.27%$21.93CLDX+0.70%$38.98BEAM+6.80%$24.67NRIX+1.39%$25.50PHVS+1.20%$38.00IRON+0.89%$69.18
Snapshot
Index-P/E-EPS (ttm)-1.65Insider Own16.99%Shs Outstand116.90MPerf Week-7.06%
Market Cap2.48BForward P/E-EPS next Y-1.56Insider Trans-1.64%Shs Float80.07MPerf Month-21.26%
Enterprise Value1.84BPEG-EPS next Q-0.50Inst Own-Short Float16.73%Perf Quarter-29.84%
Income-166.00MP/S38.69EPS this Y-14.75%Inst Trans-Short Ratio11.97Perf Half Y-30.78%
Sales64.00MP/B3.63EPS next Y17.44%ROA-36.84%Short Interest13.39MPerf YTD-39.62%
Book/sh5.84P/C3.89EPS next 5Y-ROE-38.33%52W High43.70 -49.82%Perf Year-12.19%
Cash/sh5.44P/FCF-EPS past 3/5Y-ROIC-38.70%52W Low21.76 0.76%Perf 3Y112.01%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-39.33% -Gross Margin92.15%Volatility5.62% 4.88%Perf 5Y112.22%
Dividend TTM-EV/Sales28.75EPS Y/Y TTM35.55%Oper. Margin-3432.20%ATR (14)1.37Perf 10Y-
Dividend Ex-Date-Quick Ratio9.03Sales Y/Y TTM39.13%Profit Margin-3644.21%RSI (14)27.08Recom2.10
Dividend Gr. 3/5Y-Current Ratio9.03EPS Q/Q-246.67%SMA20-15.84%Beta0.12Target Price51.33
Payout0.00%Debt/Eq0.00Sales Q/Q-78.95%SMA50-24.21%Rel Volume1.04Prev Close21.18
Employees100LT Debt/Eq-EarningsNov 04SMA200-33.76%Avg Volume1.18MPrice21.93
IPO DateFeb 09, 2021Option/ShortYes / YesEPS/Sales Surpr.-7.90% 30.73%Net Debt/EBITDA1.66Volume1,234,157Change3.54%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-20-26InitiatedBMO CapitalOutperform$58
Jul-20-26ReiteratedJefferies$45
Jun-30-26ReiteratedRBC CapitalOutperform$47 → $51
Feb-19-26ReiteratedGuggenheimBuy$45
Jan-21-26ReiteratedRBC CapitalOutperform$47
Jan-06-26ReiteratedLeerink Partners$45 → $55
Dec-02-25ReiteratedGoldman SachsNeutral$37
Oct-20-25ReiteratedH.C. WainwrightBuy$48 → $52
Aug-25-25InitiatedWells FargoOverweight$45
Mar-03-25ReiteratedUBS$35 → $41
Latest News· Times ET
Sep-15-26
Sep-15-2608:47AM
Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?Yahoo
Sep-10-26
Sep-10-2611:45PM
Biogen (NASDAQ:BIIB) versus NewAmsterdam Pharma (NASDAQ:NAMS) Financial Analysisdefenseworld.net
Sep-08-26
Sep-08-2604:26PM
How Novartis' Double-Stacked Failures Reverberated Through BiopharmaYahoo
Sep-04-26
Sep-04-2605:00PM
Stay updated with the stocks that are on the move in today's after-hours session.ChartMill
Sep-03-26
Sep-03-2612:01PM
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com
Sep-02-26
Sep-02-2604:00AM
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in Septemberglobenewswire.com
Aug-26-26
Aug-26-2604:00AM
NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026globenewswire.com
Aug-15-26
Aug-15-2611:53PM
NewAmsterdam Pharma Company N.V. $NAMS Shares Sold by Handelsbanken Fonder ABdefenseworld.net
Aug-08-26
Aug-08-2607:14PM
NewAmsterdam Pharma Company N.V. (NAMS) Analyst/Investor Day Transcriptseekingalpha.com
Aug-05-26
Aug-05-2610:10AM
NewAmsterdam Pharma Company N.V. (NAMS) Analyst/Investor Day - SlideshowSeekingAlpha
09:05AM
NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nearsmarketbeat.com
06:57AM
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimateszacks.com
03:00AM
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Resultsglobenewswire.com
Jul-29-26
Jul-29-2604:00AM
NewAmsterdam Pharma to Host Investor Day on August 5, 2026globenewswire.com
Jul-26-26
Jul-26-2609:59AM
NewAmsterdam Pharma und die Menarini Group erhalten positive Stellungnahme des CHMP mit der Empfehlung zur Erteilung einer Zulassung für Ubeslo® (Obicetrapib-Monotherapie) und Evlarco® (Festsatzkombination aus Obicetrapib und Ezetimib)prnewswire.com
Company

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
Total Revenue642346————
Cost of Goods Sold Incl. D&A
000————
Gross Profit642246————
Selling, General and Administrative Excl. Other9510670————
Research and Development144142151————
Other Operating Expense-201————
Operating Income-173-226-176————
Interest Expense
000————
Unusual Expense
———————
Non-Operating Income (Expense)622-65————
Net Income Before Taxes-166-204-242————
Income Taxes
000————
Consolidated Net Income-166-204-242————
Net Income From Continuing Operations-166-204-242————
Net Income-166-204-242————
EPS (Recurring)-1.65-1.75-2.56————
EPS (Basic, Before Extraordinaries)-1.65-1.75-2.56————
EPS (Diluted)-1.65-1.75-2.56————
EBITDA-192-242-241————
Other After Tax Adjustments
———————
Stock Option Compensation Expense
———————
Price To Earnings Ratio
———————
Price To Sales Ratio38.72173.8752.52————
Gross Margin100.0095.65100.00————
Operating Margin-270.31-982.61-382.61————
Net Margin-259.38-886.96-526.09————
Shares Outstanding11311494————
Market Capitalization2,4783,9992,416————
Operating Lease Expense
———————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$44.53$37.86$31.19$24.51$17.84● Close Price0.00M6.51M13.02M19.52M26.03MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Davidson Michael H.Chief Executive OfficerSep 14 '26Buy22.6510,000226,500792,923Sep 15
Smither John WDirectorSep 04 '26Sale25.321,60040,5128,760Sep 09
Kastelein Johannes Jacob PieterChief Scientific OfficerAug 24 '26Sale26.91125,0003,363,75069,302Aug 25
Kastelein Johannes Jacob PieterChief Scientific OfficerAug 24 '26Option Exercise0.00125,0000194,302Aug 25
Kooij Louise FrederikaChief Accounting OfficerJul 20 '26Option Exercise11.34105,0001,191,100129,353Jul 22
Kooij Louise FrederikaChief Accounting OfficerJul 20 '26Sale30.34105,0003,185,65624,353Jul 22
Kooij Louise FrederikaChief Accounting OfficerJun 22 '26Sale30.2040,0001,208,15924,353Jun 24
Kooij Louise FrederikaChief Accounting OfficerJun 22 '26Option Exercise11.2840,000451,00064,353Jun 24
Kooij Louise FrederikaChief Accounting OfficerMay 26 '26Option Exercise10.0765,000654,50089,353May 27
Kooij Louise FrederikaChief Accounting OfficerMay 26 '26Sale35.6965,0002,319,85024,353May 27
LANGE LOUIS GDirectorMar 11 '26Sale30.4244,6191,357,23010,360Mar 12
LANGE LOUIS GDirectorMar 09 '26Option Exercise11.5044,619513,11954,979Mar 10
LANGE LOUIS GDirectorMar 06 '26Sale29.4128,186828,9500Mar 10
Kastelein Johannes Jacob PieterChief Scientific OfficerMar 09 '26Option Exercise0.00101,4090170,711Mar 09
Kastelein Johannes Jacob PieterChief Scientific OfficerMar 09 '26Sale30.29101,4093,071,67969,302Mar 09
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.